0 0 0 0 0.00759493670886071 0.00632911392405061 0.00632911392405061 0.00632911392405061
Sign Up Today X
Thanks for submitting the form.
Stockreport

Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead [Yahoo! Finance]

Corbus Pharmaceuticals Holdings, Inc. (CRBP)  More Company Research Source: Yahoo! Finance
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
its two clinical programs and said FDA discussions for second-line cervical and head-and-neck programs are expected in Q1 2026. Corbus says CRB-701 is differentiated from PADCEV by a proprietary antibody, faster tumor internalization and site-specific DAR=2 "click" conjugation that produces a "hyper-stable" ADC potentially reducing peripheral neuropathy and skin toxicity while causing manageable ocular effects; a more mature safety and efficacy dataset is due in summer 2026. CRB-913 —a peripherally restricted CB1 inverse agonist for obesity—showed early SAD/MAD signals with weight loss in all treated patients (˜3% at two weeks) and low neuropsychiatric events in 112 patients, with three-month multi-dose results expected at the end of summer 2026. Interested in Corbus Pharmaceuticals Holdings, Inc.? Here are five stocks we like better. Corbus Pharmaceuticals stock: An explosive 342% YTD surge Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer' [Read more]
IMPACT SNAPSHOT EVENT TIME: CRBP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CRBP alerts
from News Quantified
CRBP
NEWS
CRBP
Earnings
CRBP
Analyst Actions
CRBP
SEC Filings
Stockreport

Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead [Yahoo! Finance]

Corbus Pharmaceuticals Holdings, Inc.  (CRBP) 
More Company Research Source: Yahoo! Finance
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
its two clinical programs and said FDA discussions for second-line cervical and head-and-neck programs are expected in Q1 2026. Corbus says CRB-701 is differentiated from PADCEV by a proprietary antibody, faster tumor internalization and site-specific DAR=2 "click" conjugation that produces a "hyper-stable" ADC potentially reducing peripheral neuropathy and skin toxicity while causing manageable ocular effects; a more mature safety and efficacy dataset is due in summer 2026. CRB-913 —a peripherally restricted CB1 inverse agonist for obesity—showed early SAD/MAD signals with weight loss in all treated patients (˜3% at two weeks) and low neuropsychiatric events in 112 patients, with three-month multi-dose results expected at the end of summer 2026. Interested in Corbus Pharmaceuticals Holdings, Inc.? Here are five stocks we like better. Corbus Pharmaceuticals stock: An explosive 342% YTD surge Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer' [Read more]
IMPACT SNAPSHOT
EVENT TIME:
CRBP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS